Obesity Drug (Wegovy) May Relieve Knee Osteoarthritis Pain

A recent study has revealed that semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, significantly alleviates knee osteoarthritis pain in obese individuals. Conducted by Novo Nordisk, the 68-week trial involved 407 participants who were randomly assigned to receive either semaglutide or a placebo, alongside exercise counseling and a reduced-calorie diet.

Results indicated that those taking semaglutide experienced an average reduction of 41.7 points on a 100-point pain scale, compared to a 27.5-point reduction in the placebo group. This remarkable improvement caught the attention of arthritis experts, with Dr. Bob Carter from the National Institute of Arthritis describing it as unprecedented for a medication.

Knee osteoarthritis affects nearly one in five Americans over 45, particularly those with obesity, who experience increased stress on their joints and associated inflammation. Current treatments often involve over-the-counter pain relievers, but these can lead to long-term health issues. For severe cases, knee replacement surgery is a common but costly option.

Semaglutide not only aids in weight loss—participants lost an average of 13.7% of their body weight—but also appears to have anti-inflammatory effects that address both mechanical and biological aspects of knee pain. This dual action could revolutionize treatment approaches, as it provides a way to tackle the root causes of pain rather than just the symptoms.

Experts hope that understanding how semaglutide works could lead to the development of more affordable treatments, potentially changing the landscape for managing knee osteoarthritis and improving the quality of life for millions.

If you are looking to buy wegovy online in UK, consult with healthcare pros like us to see how it is beneficial for you apart from weight loss.